AXIM
Axim Biotechnologies, Inc. is a company involved in nutraceutical, pharmaceutical, cosmetic and botanical products with genetic technology. It can extract and purify the cannabinoids technology having a basis on the proprietary technologies. The company makes the selling on the internet, wellness stores, and direct-to-customer trends. The company’s previous name was Axim International Inc. and it was revised to Axim Biotechnologies, Inc. in July 2014. The company is based in New York, US and was founded in the year 2010.
Axim Biotechnologies is an innovative brand in the terms of research and development of the products and includes cannabinoid biosciences through the commercial use of the newly discovered raw materials which could be a positive point for the discovery of new products. The company also has an environment-friendly approach and follows the healthy living while respective the atmosphere around. CanChew Plus™ is the flagship product of the company having 10 milligrams of hemp-derived CBD. At present, the 50 mg variant and the combinational CBD/THC gum are under the clinical trials and have the positive outlook expected from the company.
The company has a team of best managers and the high-end officials to bring the best out of the efforts in the developments, acquisitions, and partnerships. The 52-week range of the products is $1.70 – $10.39. The green standards followed by the company are the positive leads for bringing its position in an upward direction. There are pharmaceutical products with genetically controlled botanical options available with bio-material technologies. The clinical trials are being supported by the Free University of Amsterdam with the aim of treatment of chronic pain and spasticity in patients having multiple sclerosis.
Apart from this, there are cannabinoid-based concepts initiated in cooperation with the University of Wageningen, The Netherlands for the treatment of Crohn’s disease, irritable bowel syndrome and inflammatory bowel disease. The opening of two prime divisions (Cosmetic and Health division) floated for the new proprietary products within the IP portfolio. The new pharmaceutical and nutraceutical formulations have preparations designed for smoking cessation, anti-microbial formulations and new cannabinoid concepts for the clinical industry. The company imports the reputable products from Spain, Italy, Denmark, and other locations to bring the best clinical products for the industry.
Axim Biotechnologies Global Executive team has specialized professionals and team members for involving in the strategic initiatives and global operations of the sector. The company makes the promising business performance, strategies for the present and future product manufacturing, risk management, R&D, internal governance and external affairs of the company. Dr. George E. Anastassov is the CEO of the company, Lekhram Changoer as the CTO (Chief Technical Officer) and Dr. Philip A. Van Damme as the CMO (Chief Medical Officer).
Axim Biotechnologies is bringing its position towards a positive note towards the cannabis industry. The company has good relations with the customer-base and clinical support system and it is anticipated that it will have an optimistic growth with the cannabis trends moving upwards in the state of the US and Canada.